Miracell Selected as National Representative Innovative Company in Health and Diagnostics
[Medical Newspaper/Daily Newspaper=Reporter Kim Won-jun] Stem cell specialist Miracell has been selected as a “National Representative Innovative Company” by the government.
Miracell (CEO Shin Hyun-soon) announced on the 1st that it was selected as a National Representative Innovative Company by the Financial Services Commission, based on evaluations by nine government ministries, including the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare.
Miracell was selected as one of the “Health and Diagnostic Innovative Companies” in the health technology, medical device, and innovative pharmaceutical sectors, based on selection criteria established by the Ministry of Health and Welfare.
Miracell, a stem cell specialist company launched in 2009 with the introduction of Harvard University’s cell extraction technology, successfully developed a “minimally manipulated stem cell isolation and amplification source technology” in 2017. The Ministry of SMEs and Startups selected this technology as a technology development project for commercialization by small and medium-sized enterprises.
In particular, based on this technology, Miracell successfully developed and domestically produced SMART M-CELL2, a replacement for the SmartPReP2 kit developed by the Harvard Medical School Immunology Research Institute in 2018 and exported worldwide.
CEO Shin Hyun-soon stated, “Being selected as a national innovative company is very significant. This opens up a new avenue for scientifically treating rare and intractable diseases, including Parkinson’s disease and intractable chronic renal failure, using stem cells.”
Meanwhile, Miracell, which began its medical business in 1986, has been dedicated to research and development as a stem cell specialist since 2007. In particular, its biological drug manufacturing technology has been certified by the Ministry of Health and Welfare as a new medical technology for treating conditions such as acute myocardial infarction, critical limb ischemia, and cartilage defects. In addition, the company has secured core technologies through GMP, ISO13485, ISO9001, and CE certifications, as well as 22 patent applications for cell extraction technology.
Source: Medical Newspaper (http://www.bosa.co.kr)